The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | MILESTONE trial results: MRD response-adapted deferral of autoSCT in newly diagnosed myeloma
Susan Bal, MD, University of Alabama at Birmingham, Birmingham, AL, presents the results of the MILESTONE trial (NCT04991103) evaluating the use of measurable residual disease (MRD) response-adapted deferral of autologous stem cell transplantation (autoSCT) in patients with newly diagnosed multiple myeloma (MM). The study demonstrated that real-time MRD testing post-induction could guide decisions about proceeding to autoSCT, potentially sparing 25% of patients from the associated toxicities without compromising outcomes. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
